| AE/AEs | Adverse event(s) |
| AEMS | Adverse Event Monitoring System |
| CGRP | Calcitonin gene-related peptide |
| CGRP-RA/CGRP-RAs | Calcitonin gene-related peptide receptor antagonist(s) |
| CI/CIs | Confidence interval(s) |
| FDA | Food and Drug Administration |
| ICSR/ICSRs | Individual Case Safety Report(s) |
| MedDRA | Medical Dictionary for Regulatory Activities |
| PT/PTs | Preferred Term(s) |
| Q1–Q3 | Quartile 1–quartile 3 |
| READUS-PV | The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance |
| RG/RGs | Reference group(s) |
| ROR/RORs | Reporting odds ratio(s) |
| SDR/SDRs | Signal(s) of disproportionate reporting |
| SOC/SOCs | System Organ Class(es) |
| TTO | Time to onset |
| US/USA | United States/United States of America |